CBIO vs OTLK โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
OTLK Captures Institutional Edge (2โ2 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Outlook Therapeutics, Inc. Common Stock (OTLK) driven by superior Valuation, Growth & Margin while CBIO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CBIO trades at N/M Forward P/E with -1432.6% operating margin (+0.0% YoY revenue) versus OTLK at 2.9x Forward P/E and 4781.8% operating margin (-99.4% YoY). In options structure, CBIO sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against OTLK sits in BREAKDOWN (55th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CBIO Revenue | OTLK Revenue | CBIO Op. Margin | OTLK Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2017 | N/A | $0M | N/A | -941.4% | OTLK |
| FY2018 | N/A | $0M | N/A | -960.1% | OTLK |
| FY2019 | N/A | $10M | N/A | -445.6% | OTLK |
| FY2020 | $10M | N/A | -506.8% | N/A | CBIO |
| FY2021 | $0M | N/A | -5470.7% | N/A | CBIO |
| FY2022 | $0M | N/A | -63204.4% | N/A | CBIO |
| FY2023 | $0M | N/A | -392752.9% | N/A | CBIO |
| FY2025 | $10M | $0M | -1407.5% | -4744.3% | CBIO |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CBIO | OTLK | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $533.8M | $107.1M | Larger Scale | CBIO |
| Trailing P/E Ratio Valuation | N/M | 2.9x | Lower Multiple | OTLK |
| Forward P/E Ratio Valuation | N/M | 2.9x | Lower Multiple | OTLK |
| Revenue Growth (YoY) Growth | +0.0% | -99.4% | Higher Growth | CBIO |
| Operating Margin (TTM) Profitability | -1432.6% | 4781.8% | Higher Margin | OTLK |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -160.8% | -3.6% | Higher ROE | OTLK |
| 52-Week Range Position Momentum | 23% ($9โ$27) | 10% ($0โ$3) | Stronger Trend | CBIO |
| Beta / 30D Volatility Risk Regime | 1.41ฮฒ ยท 62% Vol | 1.47ฮฒ ยท 79% Vol | Lower Realized Risk | CBIO |
| Unified Institutional Score Composite Signal | 37.4 / 100 (SELL) | 48.6 / 100 (HOLD) | Higher Composite | OTLK |